Related Experiment Video

Updated: Mar 21, 2026

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice
08:55

A Practical Guide for the Production and PET/CT Imaging of 68Ga-DOTATATE for Neuroendocrine Tumors in Daily Clinical Practice

Published on: April 17, 2019

19.1K

PET/CT in Neuroendocrine Tumors

Paolo Castellucci1, Valentina Ambrosini1, Giancarlo Montini1

  • 1Department of Nuclear Medicine, Policlinico S.Orsola-Malpighi, University of Bologna, Padiglione 30, Via Massarenti 9, 40138 Bologna, Italy.

PET Clinics
|May 10, 2016
PubMed

Insights

Positron Emission Tomography (PET) offers valuable insights into neuroendocrine tumors (NETs). This review analyzes PET

Area of Science:

  • Oncology
  • Nuclear Medicine
  • Radiopharmaceuticals

Background:

  • Neuroendocrine tumors (NETs) are rare neoplasms originating from neuroendocrine cells.
  • NETs commonly occur in the bronchus, lungs, or gastroenteropancreatic tract.

Purpose of the Study:

  • To review the applications of Positron Emission Tomography (PET) in managing neuroendocrine tumors (NETs).
  • To analyze the utility of commonly used radiopharmaceuticals in staging, restaging, and detecting unknown primary NETs.
  • To assess the role of PET in monitoring therapy response for various NET treatments.

Main Methods:

  • Review of existing literature and studies on PET imaging in NETs.
  • Analysis of data concerning receptor and metabolic positron-emitter radiopharmaceuticals.
  • Evaluation of PET's effectiveness in different clinical scenarios of NET management.

Main Results:

  • PET imaging demonstrates significant potential in staging and restaging NETs.
  • PET can aid in detecting unknown primary NETs.
  • PET is effective in assessing and monitoring response to various NET therapies.

Conclusions:

  • Positron Emission Tomography (PET) is a crucial tool in the comprehensive management of neuroendocrine tumors (NETs).
  • The application of receptor and metabolic radiopharmaceuticals in PET enhances diagnostic accuracy and therapeutic monitoring for NET patients.
Keywords:
DiagnosisNeuroendocrine tumorsPositron emission tomography

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K
Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats06:32

Operating Procedures of the Electrochemotherapy for Treatment of Tumor in Dogs and Cats

Published on: October 24, 2016

27.9K

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
8.0K